Stockscreener 앱 받기
2.56
6.57%
-0.18
시간 외 거래:
2.56
전일 마감가:
$2.74
열려 있는:
$2.66
하루 거래량:
324.15K
Relative Volume:
1.03
시가총액:
$100.00M
수익:
$2.76M
순이익/손실:
$-49.12M
주가수익비율:
-1.7067
EPS:
-1.5
순현금흐름:
$-46.21M
1주 성능:
-1.92%
1개월 성능:
-7.25%
6개월 성능:
-58.91%
1년 성능:
-49.80%
1일 변동 폭
$2.52
$2.8805
1주일 범위
$2.43
$3.12
52주 변동 폭
$2.43
$8.8699
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
명칭
Orchestra Biomed Holdings Inc
전화
646-343-9298
주소
150 UNION SQUARE DRIVE, NEW HOPE
OBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
2.56 | 100.00M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | BTIG Research | Buy |
| 2025-01-02 | 개시 | Barclays | Overweight |
| 2024-08-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-25 | 개시 | B. Riley Securities | Buy |
| 2024-01-19 | 개시 | Jefferies | Buy |
| 2023-02-24 | 개시 | Piper Sandler | Overweight |
| 2023-02-07 | 개시 | Chardan Capital Markets | Buy |
모두보기
Orchestra Biomed Holdings Inc 주식(OBIO)의 최신 뉴스
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
OBIO: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
How did Orchestra BioMed Holdings Inc (OBIO) fare last session? - uspostnews.com
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment - MyChesCo
Orchestra Biomed sees $149,201 stock purchase by RTW Investments By Investing.com - Investing.com Australia
Orchestra BioMed Holdings Inc [OBIO] Records 200-Day SMA of $5.25 - knoxdaily.com
Orchestra BioMed to Present at Jefferies Global Healthcare Conference - MyChesCo
Geode Capital Management LLC Boosts Stock Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
FDA approves head-to-head trial of Orchestra BioMed’s balloon - Investing.com
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy - Diagnostic and Interventional Cardiology
FDA Clears Orchestra BioMed's Virtue SAB Trial To Treat Coronary ISR - Nasdaq
Orchestra BioMed (OBIO) Gains FDA Nod for Updated Coronary ISR T - GuruFocus
Orchestra BioMed Receives FDA Approval for IDE Amendment - TipRanks
Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon - marketscreener.com
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon - GlobeNewswire
Orchestra BioMed's Revolutionary Sirolimus Balloon Gets FDA Green Light for Head-to-Head Trial - Stock Titan
Orchestra BioMed (NASDAQ:OBIO) Shares Down 6.1% – Time to Sell? - Defense World
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewswire
Orchestra BioMed Secures Triple Conference Lineup: CEO Sets Major Investor Presentations - Stock Titan
Analyzing PetVivo (NASDAQ:PETV) & Orchestra BioMed (NASDAQ:OBIO) - Defense World
Orchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025 - MSN
Orchestra BioMed stock holds Buy rating, $12 target from H.C. Wainwright - Investing.com Canada
Financial Metrics Unveiled: Orchestra BioMed Holdings Inc (OBIO)’s Key Ratios in the Spotlight - DWinneX
Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy - MSN
When (OBIO) Moves Investors should Listen - news.stocktradersdaily.com
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - Investing News Network
Orchestra BioMed Hosts Symposium on Breakthrough AVIM Therapy for Uncontrolled Hypertension at HRS 2025 Annual Meeting - Nasdaq
FDA Breakthrough Therapy for 7.7M Hypertension Patients: New Clinical Data | OBIO Stock News - Stock Titan
Examining the Potential Price Growth of Orchestra BioMed Holdings Inc (OBIO) - knoxdaily.com
Investors Take Advantage Of 0.70% Gain In Orchestra BioMed Holdings Inc (NASDAQ: OBIO) - Stocksregister
FDA grants breakthrough status to Orchestra BioMed’s AVIM therapy By Investing.com - Investing.com Canada
Orchestra BioMed Holdings Inc: A Year of Highs, Lows, and Market Resilience - investchronicle.com
There Are Mixed Signals on the Chart for Orchestra BioMed Holdings Inc (OBIO) - uspostnews.com
FDA grants breakthrough status to Orchestra BioMed’s AVIM therapy - Investing.com Australia
Orchestra BioMed shares surge on FDA breakthrough designation By Investing.com - Investing.com Nigeria
Orchestra BioMed (OBIO) Gains FDA Breakthrough Device Status for AVIM Therapy | OBIO Stock News - GuruFocus
Orchestra BioMed shares surge on FDA breakthrough designation - Investing.com Australia
Orchestra BioMed Receives FDA Breakthrough Device Designation for Atrioventricular Interval Modulation Therapy to Address Uncontrolled Hypertension - Nasdaq
Orchestra BioMed (OBIO) Receives FDA Breakthrough Device Designation for AVIM Therapy - StreetInsider
Orchestra's Revolutionary Blood Pressure Device Earns FDA Breakthrough Status: 7.7M Patients Could Benefit - Stock Titan
Orchestra BioMed Reports 2024 Financial Results and Advances Cardiovascular Therapy - MSN
Orchestra Biomed Holdings Inc (OBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):